Phuturdex › Drugs › Trimetazidine
Drugs in development · updated 5 November 2026
Trimetazidine: clinical trials and development status
As of 5 November 2026 Trimetazidine is in 3 active clinical trials (recruiting or ongoing, phases I–III) for Aluminum Phosphide Poisoning, Diabetic Peripheral Neuropathic Pain (DPN), Transthyretin Cardiac Amyloidosis (conditions named by the trials, not coded by the NLM). The most advanced phase is III.
Summary updated every week · data as of 5 November 2026. In Phuturdex you can follow Trimetazidine and get an email at every change or safety alert.
Sign in free →Conditions named by the trials
The trials of this drug have no disease codes assigned by the U.S. National Library of Medicine: the conditions are shown as written by the trials, with no disease page.
- Aluminum Phosphide Poisoning
- Diabetic Peripheral Neuropathic Pain (DPN)
- Transthyretin Cardiac Amyloidosis
Everything on Trimetazidine
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 5 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.